124 results
Page 2 of 7
8-K
EX-99.2
416jsmwrev mr
2 Nov 20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
4:11pm
8-K
EX-10.3
kl4mthe8zq5d9zeyk
31 Aug 20
Departure of Directors or Certain Officers
4:36pm
8-K
EX-10.2
n8imr
31 Aug 20
Departure of Directors or Certain Officers
4:36pm
8-K
EX-10.1
u16vehvqv1d98mvet
31 Aug 20
Departure of Directors or Certain Officers
4:36pm
8-K
EX-99.1
v0y5uqv y42w2xb5yi4
4 Aug 20
Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress
7:13am
8-K
EX-99.1
eshxre
14 Jul 20
Karyopharm Announces Preliminary Unaudited Second Quarter
7:08am
8-K
EX-99.1
aeudjuvjvt7pg
22 Jun 20
Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of
4:34pm
424B5
za1nvbi8 raq
5 May 20
Prospectus supplement for primary offering
5:05pm
8-K
EX-99.1
er6 pb3ldn
4 Mar 20
Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock
4:22pm
424B5
mmfrzfxp4qukps
4 Mar 20
Prospectus supplement for primary offering
4:15pm
424B5
mq0uvt
2 Mar 20
Prospectus supplement for primary offering
4:21pm
8-K
EX-99.1
fb9bmqrri8q
2 Mar 20
Other Events
7:05am
S-3ASR
y6zxv3e9yzcbhfy vl9d
26 Feb 20
Automatic shelf registration
8:35am
8-K
EX-99.1
qgd286
13 Feb 20
Karyopharm Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress
7:09am
8-K
EX-99.1
tziixfz93w4qqij08g
13 Jan 20
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Product Sales for XPOVIO® (selinexor) and Provides Commercial Update
7:12am
8-K
EX-99.1
0fjd3k81o 00j
9 Dec 19
Karyopharm Reports New and Updated XPOVIO® (Selinexor) Data in Relapsed or
7:30am
8-K
EX-99.2
peo2yqz
9 Dec 19
Karyopharm Reports New and Updated XPOVIO® (Selinexor) Data in Relapsed or
7:30am